TECHNOLOGYWe Deliver
Using A novel approach to RNA delivery, Tiba is developing next generation vaccines and gene therapies with superior potency, stability, and safety
SOLVING A PROBLEMThe world needs better RNA delivery
Today most RNA medicines rely on a decades-old technology—lipid nanoparticles (LNPs)—to enable administration to the human body.
LNPs are delicate nanoscale shells of positively-charged amino lipids that encapsulate the negatively-charged RNA. However, studies have shown that these LNP components can lead to undesirable, dose-limiting toxicity and inflammation. This is also a highly litigated patent space where a small number of early innovators are able to demand handsome licensing fees that chill new applications. Tiba has developed a portfolio of issued patents and patent filings across the globe that range from novel dendrimer chemistries to nucleic acid design.
WITH NOVEL SOLUTIONSTiba is disrupting the field of RNA medicine
We are introducing a new class of fully synthetic biodegradable nanoparticles that overcome the limitations of LNPs.
Using a rational design approach, Tiba scientists can maximize the effective dose of RNA administered to the patient with reduced side effects. We engineer the properties necessary for RNA compaction and delivery into a proprietary class of fully biodegradable, high molecular weight molecules. Because these molecules are more effective at complexing with RNA than small lipids, we can drastically reduce the need for large quantities of excipient carrier materials. Tiba’s expanding intellectual property portfolio covers a wide array of delivery chemistries that can be customized to meet different RNA product profiles, including applications spanning:
- Vaccines
- Immuno-oncology
- Gene delivery
- Gene editing
Keep connected with us
© 2024 Tiba Biotech LLC. All rights reserved